These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 26766168)

  • 1. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria.
    Lee GS
    Ann Acad Med Singap; 2005 Jan; 34(1):24-30. PubMed ID: 15726216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic management of diabetic nephropathy.
    Vivian EM; Rubinstein GB
    Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression.
    Strippoli GF; Craig MC; Schena FP; Craig JC
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S153-5. PubMed ID: 16565242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
    Isaacs AN; Vincent A
    J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
    Taheri S; Asim M; Al Malki H; Fituri O; Suthanthiran M; August P;
    Trials; 2018 Apr; 19(1):230. PubMed ID: 29665833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
    Krairittichai U; Sarinnapakorn V; Mahannopkul R; Ainwan P
    J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S40-7. PubMed ID: 29927180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
    Yamout H; Lazich I; Bakris GL
    Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.
    Hirst JA; Taylor KS; Stevens RJ; Blacklock CL; Roberts NW; Pugh CW; Farmer AJ
    Kidney Int; 2012 Apr; 81(7):674-83. PubMed ID: 22189841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.